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Abstract
Cryoglobulinemia is a rare disease caused by the specific antibodies which precipitate at low temperatures 
being present within the blood serum. It is observed in the course of disorders such as autoimmune diseases, 
lymphoproliferative neoplasms, and infectious diseases — mainly HCV infections. Three types of cryoglobulinemia 
have been identified, differing in the type of immunoglobulins involved and symptoms being manifested. We are 
presenting a case of a 61-year-old female patient with type I cryoglobulinemia related to Sjögren’s syndrome 
and complicated by monoclonal gammopathy of undetermined significance.
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Introduction
Cryoglobulinemia is a rare disease (1 case per 100,000 
individuals) [1], consisting of antibodies which precip-
itate at low temperatures (i.e. temperatures of below 
37˚C) being present within the blood serum [2]. It is 
observed in the course of various disorders such as 
lymphoproliferative neoplasms, autoimmune diseases, 
and viral infections, with HCV being the main agent 
responsible for the latter [2]. Three types of cryoglob-
ulinemia have been identified, differing in the type of 
immunoglobulins involved, the most common being 
referred to as type II. We are presenting a case of 
a 61-year-old female patient with monoclonal cryoglob-
ulinemia (of type I) related to Sjögren’s syndrome and 
complicated by monoclonal gammopathy of undeter-
mined significance (MGUS).
Case report
A 61-year-old female patient with a 4-year history of 
Sjögren’s syndrome was admitted to the Department 
of Angiology, Systemic Hypertension, and Diabetology 
with calf ulcers which had appeared several years before 
presentation. Upon admission, the patient was in severe 
overall condition with the disease affecting both calves 
and involving extensive and strongly adherent necrotic 
lesions reaching down to the fascial and muscular levels 
and requiring administration of high-dose opioid anal-
gesics (Figs 1, 2). Laboratory investigations revealed 
features of activated inflammatory response (CRP 43 
mg/l [reference range 0–5 mg/l], leukocytosis12.14 
G/l, normocytic anemia) and reduced levels of com-
plement C4 [< 0.08 g/l, reference range 0.1–0.4 g/l] 
with unremarkable levels of complement C3 [1.46 g/l, 
reference level 0.9–1.8 g/l]. High levels of rheumatoid 
factor [323 IU/ml] and presence of anti-Ro (SS-A) and 
anti-La (SS-B) antibodies at the titer of 1:3200 were also 
demonstrated. No deviations from reference ranges 
were identified in urinalysis results. HBV and HCV 
screening tests were negative.
The scope of diagnostic laboratory investigations 
was broadened due to the unclear origin of severe 
necrotic lesions. Refrigeration test revealed the pres-
ence of cryoglobulins, later to be confirmed in serum 
immunofixation assays (monoclonal IgM kappa immu-
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noglobulin). Despite numerous additional assays (such 
as pANCA, cANCA, anti-dsDNA titers, HCV and HBV 
screening assays) symptoms of vasculitis related to 
other system dysfunctions were excluded. The patient 
had been subjected to hematological consultation which 
revealed monoclonal gammopathy of undetermined 
significance (MGUS). On the basis of clinical presenta-
tion and the results of laboratory investigations, the 
patient was diagnosed with vasculitis in the course of 
type I cryoglobulinemia secondary to MGUS which had 
developed as a complication of previously diagnosed 
Sjögren’s syndrome.
Due to the aggressive course of the disease and the 
risk of resulting limb loss, a decision to initiate immuno-
suppressive therapy was made following hematological 
consultation. Between May 2014 and October 2016, 
a total of 7.6 g of cyclophosphamide was administered 
in pulses as an addition to local management (including 
mechanical debridement of ulcers under general anes-
thesia) to achieve partial healing of lesions. In October 
2014, the patient was diagnosed with asymptomatic 
proximal deep vein thrombosis and vertebral fractures 
at levels L2 and L4 (treated by vertebroplasty at the De-
partment of Neurosurgery); after several days, another 
two fractures at Th12 and L1 were detected (and also 
subjected to surgical treatment). During subsequent 
hospitalizations, several episodes of airway infections 
were observed as was pulmonary and tricuspid regur-
gitation and dilatation of the aortic bulb.
Establishment of an efficient maintenance immuno-
suppression regimen was a significant problem. As the 
attempts to introduce methotrexate and azathioprine 
had failed (several airway infections), cyclosporine was 
identified as the best-tolerated drug. Currently, the 
ulcers are nearly completely healed (Figs 3, 4), and the 
patient is capable of ambulating using a Zimmer frame. 
Laboratory investigations continue to show elevated 
CRP levels (12 mg/l), microcytic anemia, and reduced 
GFR (78 ml/min/1.73 m2). Cyclosporine is found to be 
present at optimum (therapeutic) levels.
Discussion
Sjögren’s syndrome is a connective tissue disorder char-
acterized by particularly profound and dangerous immu-
nological disorders. Observations include increased pro-
liferation of B cells, and, as a consequence, production 
of numerous autoantibodies (anti-Ro/SSA, anti-La/SSB, 
AMA, anti-centromere antibodies) and rheumatoid fac-
tor as well as increased expression of pro-inflammatory 
cytokines, i.e. IL-1b, IL-6, IL-17, TNF-a, interferon g [3]. 
As a result of numerous immunological mechanisms, the 
risk of non-Hodgkin lymphoma (NHL) is 4 to 44 times 
higher in patients with Sjögren’s syndrome as compared 
to the overall population [4]. Monoclonal antibodies 
were detected in 7–22% of patients [5, 6]; in some 
cases, the synthesized gamma-globulins presented with 
cryoglobulin features.
Figure 1. Lesions before admission to the hospital
Figure 2. Lesions before admission to the hospital
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Three types of cryoglobulinemia are identified on the 
basis of laboratory investigations: monoclonal (type I) 
cryoglobulinemia, mixed monoclonal/polyclonal 
(type II) cryoglobulinemia and polyclonal (type III) 
cryoglobulinemia. Each type may be manifested by 
a different set of symptoms. Type I cryoglobulinemia 
is characterized mainly by the presence of skin lesions 
such as purple-colored papulae on lower limbs, livedo 
reticularis, and Raynaud’s phenomenon as well as the 
most serious lesions including ulcers and tissue necrosis 
which were predominant in the clinical presentation of 
the reported patient. Types II and III more frequently 
present with symptoms within other systems, with 
strong muscle and joint pains becoming more intensive 
at lower temperatures, peripheral polyneuropathy, 
hepatic dysfunction, respiratory symptoms (cough, 
dyspnea, pleuritis) or membranoproliferative glomeru-
litis. These symptoms are associated with cryoglobulins 
being deposited within small vessels (mainly capillaries, 
venules, or arterioles) and present in the blood.
Symptoms observed in the reported case, i.e. skin 
lesions including calf ulcers and soft tissue necrosis 
correspond to type I cryoglobulinemia. Other disor-
ders taken into consideration in differential diagnosis 
included i.a. Schnitzler syndrome (absence of typical 
urticaria, recurrent fever, lymphadenopathy, or joint 
pains), secondary vasculitis related to Sjögren’s syn-
drome and Waldenström macroglobulinemia (absence 
of recurrent epistaxis).
No standard of treatment has been established to 
date for cryoglobulinemia. The treatment must target 
the diseases involved in the development of the dis-
order. Cryoglobulinemia-causing neoplasms (chronic 
lymphocytic leukemia, Waldenström macroglobuline-
mia, and other types of lymphoma) are treated with 
chemotherapy, sometimes with adjuvant radiotherapy. 
Cryoglobulinemia in the course of HCV or HBV in-
fection (mixed type II or type III cryoglobulinemia) is 
treated with antiviral regimens (the authors’ experience 
suggests that eradication of the hepatitis C virus leads 
to symptom resolution). Patients with symptomatic 
cryoglobulinemia and vasculitis syndromes, as in the 
presented case, are treated with immunosuppressants.
Cyclophosphamide (an alkylating agent) was shown 
to efficiently induce remission in the presented case; 
however, the choice of remission maintenance treatment 
proved to be problematic. Glucocorticosteroids cause 
resolution of symptoms while simultaneously reducing 
cryocrit values. Cytotoxic drugs such as azathioprine 
(a purine antimetabolite) and methotrexate (a folic 
acid antagonist) ) facilitate inhibition of immunoglob-
ulin production by B cells. In the reported patient, 
however, this treatment proved ineffective due to 
disease complications. Cyclosporine was identified as 
the most effective and well-tolerated treatment. Cy-
closporine belongs to the group of calcineurin inhibitors 
and inhibits humoral and cellular immune responses 
modifies chronic inflammatory processes, reduces the 
production and secretion of lymphokines (such as IL-2) 
and T-cell growth factor (TCGF) as well as affects the ac-
tivity of T helper cells. In addition, cyclosporine inhibits the 
induction phase of the lymphatic cell proliferation process.
Figure 4. The left calf after treatment
Figure 3. The left calf after treatment
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We are presenting this case due to the extraordinary 
intensity of necrotic lesions resulting from the presence 
of monoclonal proteins with cryoglobulin properties 
rather than from secondary vasculitis. It appears that 
every case of unexplained skin lesions or necrotic le-
sions in patients suffering from Sjögren’s syndrome or, 
in a broader sense, an autoimmune disease, requires 
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